CPC H01J 49/0431 (2013.01) [A61B 10/0045 (2013.01); B01L 3/502 (2013.01); G01N 1/02 (2013.01); G01N 30/72 (2013.01); G01N 33/487 (2013.01); G01N 33/574 (2013.01); G01N 33/6848 (2013.01); H01J 49/0031 (2013.01); H01J 49/04 (2013.01); B01L 3/0293 (2013.01); B01L 2200/0605 (2013.01); B01L 2400/0655 (2013.01); G01N 2001/028 (2013.01); G01N 2001/4061 (2013.01); G01N 2560/00 (2013.01)] | 17 Claims |
1. A method for assessing tissue samples from a subject, the method comprising:
(a) applying a fixed or discrete volume of a solvent to a tissue site in the subject;
(b) collecting the applied solvent to obtain a liquid sample;
(c) subjecting the liquid sample to mass spectrometry analysis, thereby obtaining a mass spectrometry profile comprising a plurality of mass-to-charge (m/z) ratios; and
(d) characterizing the liquid sample based on the mass spectrometry profile;
wherein characterizing the liquid sample comprises determining whether the tissue site comprises:
normal lung, breast, ovarian, or thyroid cells;
benign lung, breast, ovarian, or thyroid cells; or
cancerous lung, breast, ovarian, or thyroid cells;
wherein when the profile comprises at least 5 mass-to-charge (m/z) ratios selected from the group consisting of 175.02, 187.01, 201.04, 215.03, 306.08, 313.16, 330.98, 332.90, 357.10, 409.23, 615.17, 722.51, 744.55, 747.52, 748.52, 771.52, 773.53, 861.55, 863.57, 885.55, and 886.55, then the tissue site is identified as comprising cancerous lung cells;
wherein when the profile comprises at least 3 mass-to-charge (m/z) ratios selected from the group consisting of 124.01, 175.02, 175.03, 283.27, 313.16, and 341.27, then the tissue site is identified as comprising cancerous ovarian cells;
wherein when the profile comprises at least 5 mass-to-charge (m/z) ratios selected from the group consisting of 175.02, 191.02, 191.05, 283.27, 341.27, 353.16, 432.20, 433.21, 615.17, 822.47, and 822.48, then the tissue site is identified as comprising cancerous thyroid cells; and
when the profile comprises at least 5 mass-to-charge (m/z) ratios selected from the group consisting of 187.04, 268.80, 279.92, 283.27, 341.27, 345.16, 381.21, 687.51, 742.54, and 766.54, then the sample is identified as comprising cancerous breast cells.
|